Can phi density accurately predict risk for clinically significant prostate cancer?

A new article in BJU International has suggested the possibility that Prostate Health Index density (i.e., a patient’s phi score divided by his prostate volume) may be able to predict the probability of a finding of clinically significant prostate cancer on biopsy. … READ MORE …

Oncotype DX and risk for clinically significant prostate cancer

Last September we asked whether the Oncotype DX test for risk of prostate cancer developed by Genomic Health was “ready for prime time”. In a media release issued earlier this week, the company said that it was. However, there are a number of unresolved issues that are likely to impact the uptake of this new test. … READ MORE …

Better characterization, diagnosis of insignificant prostate cancer

The full text of a “consensus” review entitled “The contemporary concept of significant versus insignificant prostate cancer” has just been published on line in European Urology. The authors include opinion-leaders from the USA, France, Italy, Germany, Sweden and Canada. … READ MORE …

What is the risk of NOT treating PSA-detected prostate cancer?

A new article in the May issue of Cancer Epidemiology, Biomarkers and Prevention appears to be a first attempt to project population-based probabilities of the occurrence of clinically significant prostate cancer among men who are diagnosed with prostate cancer but who receive no treatment. … READ MORE …